Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC is the United States subsidiary of Merck & Co., Inc., one of the world's largest pharmaceutical companies by revenue and clinical trial activity. MSD — as the company is known outside the US — has been a driving force in vaccine development for over a century and more recently became central to the immune-oncology revolution through the development of pembrolizumab (Keytruda), now the world's top-selling cancer drug and the most widely studied oncology agent in clinical trial history.
Keytruda's clinical program alone spans hundreds of registered trials across 30+ cancer indications, encompassing first-line and later-line treatment, monotherapy, and combinations with chemotherapy, targeted agents, and bispecific antibodies. Beyond oncology, Merck's clinical portfolio includes antiviral programs (molnupiravir for COVID-19, HIV treatment research), cardiovascular disease, diabetes (sitagliptin/Januvia and successors), and vaccines including HPV (Gardasil 9), varicella, rotavirus, and investigational mRNA and subunit vaccines for respiratory viruses.
Merck-sponsored trials operate through the company's Global Clinical Trials organization and are conducted in partnership with academic centers, cooperative research networks, and industry research sites across more than 90 countries. Clinical data from MSD trials are submitted to regulatory agencies under strict FDA and EMA guidelines. Participants are monitored throughout enrollment by qualified clinical research coordinators at each trial site.